Home » NITROMED SHARES PLUNGE ON SOFT DRUG SALES
NITROMED SHARES PLUNGE ON SOFT DRUG SALES
Shares of NitroMed Inc. tumbled 31 percent Tuesday after the pharmaceutical maker said sales of its heart-failure drug, approved for use only by blacks, again fell short of expectations. NitroMed also said it expects net sales of the 10-month-old drug BiDil will amount to $20 million this year, less than half of the $44 million consensus estimate of analysts surveyed by Thomson Financial.
Westfall Weekly News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May